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BioglassAbstract Endothelial dysfunction is a broad pathological disorder of the endothelium (innermost
layer of blood vessels) which is assigned by vasoconstriction, thrombosis and ischemic diseases,
alone or with other disorders such as coronary artery disease, hypertension and atherosclerosis.
The fundamental imperfection of endothelial layer injury due to decrease in the number of func-
tional endothelial progenitor cells and inhibition of endothelial progenitor cell differentiation,
resulting into impairment of angiogenesis, vasculogenesis, tube formation properties and endothe-
lial regeneration. Multiple significant therapeutic achievements in impediment and treatment of vas-
cular diseases include the use of antithrombotic agents, statin class of drugs, lifestyle changes, and
revascularization therapies. Nevertheless, a certain number of patients with endothelial dysfunction
disease are resistant to the usual therapies, so new therapeutic strategies for endothelial dysfunction
disease are urgently needed. Recent studies show that stem cell-based therapy has important pro-
mise for repair and treatment of vascular dysfunction. In this study, we describe a novel choice
for treatment of endothelial dysfunction in vascular regenerative medicine via the human endome-
trial stem cell culture (as a new source for the increasing the number of endothelial progenitor cells)
with bioglass (angiogenic agent) to investigate the enhancing expression of CD34, CD31 and gene
markers of endothelial progenitor cells and endothelial cells. In the end, application of immuno-
privileged, readily available sources of adult stem cells like human endometrial stem cells with
bioglass would be a promising strategy to increase the number of endothelial progenitor cells
and promote spontaneous angiogenesis needed in endothelial layer repair and regeneration.
 2015 Tehran University of Medical Sciences. Published by Elsevier Ltd. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Endothelial layer dysfunction is a sign of beginning of vascular
diseases such as coronary artery disease [1], hypertension [2],
and vascular complications of diabetes [3], hypercholes-
terolemia [4], chronic renal failure [5], and atherosclerosis [6].
It is closely attributed to risk factors containing family history,
age and ethnicity (cannot be changed), smoking, unhealthy
diets, obesity, physical inactivity, diabetes, high cholesterol
levels, and hypertension (can be changed or treated) [7–10].
Recent studies showed that stem cells therapy and transplanta-
tion of progenitor cells have opened up new promising strate-
gies in treatment of vascular diseases by vascular regeneration
and enhancing angiogenesis [11–14]. Stem cells are undifferen-
tiated cells characterized by theirs potency to proliferate,
develop specific committed progenitor cells and their capacity
to differentiate tissue specific cells [15]. The use of embryonic
stem (ES) cells for clinical trials is high on the political and eth-
ical agenda. The process to obtain bone marrow stem cells is
invasive procedure and can cause bleeding, infection and
chronic pain, so restricting a broad usage of bone marrow stem
cells in cell therapy. Finding a suitable source for stem cell-
based therapy that can be applied in the clinic for vascular
regeneration and repair is a challenge. Angiogenesis is the
new blood vessels formation from proliferation of endothelial
cells (differentiated and mature cells) of pre-existing blood ves-
sels [16] but vasculogenesis is the de novo formation of blood
vessels using mesodermal stem cells (undifferentiated cells) into
the endothelial cells lineage [17]. In vasculogenesis process, the
stem cells that are differentiated to form endothelial progenitor
cells (EPCs), a typical precursor for mature endothelial cells
[18]. A stem cell with more limitation of its differentiation
capacity or a unipotent stem cell is called a progenitor and
can generally differentiate into a particular type of cell.
Two common sources of EPCs exist in the human, one inFig. 1 Schematic illustration of the induced angiogenesis and tubthe circulating blood and bone marrow and the other residing
within the vessels wall [19–21]. In vivo studies showed that
EPCs contributed to endothelial cells turnover and so could
be used therapeutically to increase vascular function [22]. Vas-
cular regeneration and angiogenesis are influenced by the num-
ber of functional EPCs, stimulation of EPCs differentiation,
critical concentrations of Calcium(Ca), Copper(Cu), Magne-
sium(Mg) ions and formed by cytokines and various growth
factors including FGFs, EGF, PDGF, VEGFs, and IGF-I
[23]. In this hypothesis, we studied angiogenic and tube forma-
tion capacities of human endometrial stem cells (uncommon
source of EPCs) in the presence of angiogenic agent such as
BG, and therapeutic possibilities of human endometrial stem
cells therapy with angiogenic materials (as scaffolds) for new
blood vessel formation. Thus, the plan currently hypothesized
to provide a novel therapeutic strategy and ameliorate
endothelial dysfunction may result in decreased mortality
and morbidity in vascular injury.
The hypothesis
In recent years, the therapeutic proficiency of stem and pro-
genitor cells in endothelial vascular disorder is an important
and exciting aspect of cardiovascular research. There are
stem/progenitor cells within the blood vessel walls and in the
circulating blood system (originated from bone marrow) that
are capable of differentiating into endothelial cells. Previous
studies showed that bioglass (BG) stimulate the secretion of
basic fibroblast growth factor (bFGF) and vascular endothe-
lial growth factor (VEGF) (angiogenic growth factors) from
human fibroblast cells, and conditioned medium from human
fibroblast cells significantly enhanced the proliferation of
human microvascular endothelial cells (angiogenesis in vascu-
lar endothelial cells). This material promotes vasculogenesis
and angiogenesis in the presence of endothelial growth factorse formation hypothesis using bioglass (BG) scaffold or extract.
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cells, and non-stem like cells such as differentiated cells, pro-
genitor cells (Fig. 1). Thus, our hypothesis was that application
of human endometrial stem cell (as a new source for increasing
the number of EPCs) with BG (as extract or scaffold) may
increase number of EPCs, so if lost endothelial cells could be
expeditiously substituted by exogenous EPCs that are origi-
nated from human endometrial stem cells, enhanced vascular
repair and regeneration might be achieved.Evaluation of hypothesis
Endometrial stem cells properties
Human endometrial stem cells (hEnSCs) were demonstrated to
have dynamic remodeling roles in uterine cyclic renewal [24]
and partake a distinguished contribution in regeneration and
repair of endometrium [25]. They were showed to be
immuno-privileged in comparison to other stem cell types, iso-
lating hEnSCs a new insight for stem-cell-based therapies and
rendering these stem cells as a novel candidate in regenerative
medicine. It has been demonstrated that hEnSCs proliferate
rapidly in cell culture, as well as have anti-inflammatory char-
acteristics increasing the wound repair with new tissue forma-
tion and abatement of fibrosis [26]. Their differentiation
potential to mesoderm-derived cell lineages, such as neuron
[27], osteoblasts [28], cartilage [29], and hepatocyte [30] were
previously shown. As shown in recent studies the hEnSCs
are positive for mesenchymal stem cell markers such as
CD44, CD90, CD146, and CD105 and are negative for
CD34 (endothelial progenitor cell marker) and CD31 (mature
endothelial cell marker) [31].
Angiogenic properties of bioactive glass
Bioglass (BG), family of bioactive glasses, because of its high
bioactivity, biocompatibility, and composition stimulates
osteogenesis and angiogenesis in vivo. BG, depending on its
application, can be synthesized with various chemicals like
SiO2, Na2O, CaO, and P2O5. These chemical components
can be substituted with different functional groups such as
MgO, K2O, and CaF2. Recent studies have shown the capacity
of bioactive glass to increase angiogenesis through dissociationFig. 2 Demonstrative illustration of the stages that require in th
endothelial progenitor cells and mature endothelial cells via the bioglaproducts of BG, which is important to many applications in
the wound healing and tissue repair and regeneration. Induc-
ing endothelial differentiation of hEnSCs with biomemetic
BG material may improve the number of EPCs, endothelial
regeneration and neovascularization due to angiogenesis.
Description of the study
Hypothetical sketch (Fig. 2) involves different concentration of
BG extracts for the assessment of a suitable BG dose for induc-
ing spontaneous angiogenesis in hEnSCs. Our propounded
process involves the following steps:
1. The sol–gel prepared BG powder (SiO2, MgO, CaO, and
P2O5) was synthesized according as described previously
[32]. The solution preparation was described as follows:
13.13 g of tetraethyl orthosilicate (TEOS) was mixed into
30 ml of 0.1 M nitric acid (HNO3), the mixture was agitated
for 45 min at room temperature for the acid hydrolysis of
TEOS to begin approximately to completion of reaction.
The other reagents were added in progression allowing an
hour for each material to entirely react: 0.91 g of triethyl
phosphate (TEP), 6.14 g of calcium nitrate tetra-hydrate
(Ca(NO3)2_4H2O), and 1.28 g of magnesium nitrate hex-
ahydrate (Mg(NO3)2_6H2O). The solution was preserved
in an isolated Teflon container for 10 days at room temper-
ature to provide the polycondensation and polymerization
reaction to occur until the BG gel structure was formed.
Then, the gel was heated at 70 and 120 C for 3 days to
remove all the water. The dry powder was heated for 24 h
at 600 C for sintering and nitrate elimination. Energy-
dispersive X-ray spectroscopy (XRD) and Fourier trans-
form infrared (FTIR) spectroscopy were performed to
assess the atomic elemental analysis and chemical band
structure of powder, respectively.
2. Isolation of hEnSCs from 30 years old donor without any
urogenital diseases. The patient was apprised about the
study and signed the consent forms voluntarily. The sample
was maintained in 10 ml of Hanks’ balanced salt solution
(HBSS) with 1% (v/v) penicillin/streptomycin. The tissue
was digested in 0.3% (w/v) collagenase type I at 37 C for
45 min, neutralized by Dulbecco’s Modified Eagle Medium
(DMEM) supplemented with 10% fetal bovine serum
(FBS) and 1% (v/v) penicillin/streptomycin, ande human endometrial stem cells (hEnSCs) differentiation into
ss (BG) extract induction.
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resuspended in DMEM containing 10% FBS and 1% peni-
cillin/streptomycin. Cell culture was incubated in 5% (v/v)
CO2 at 37 C for 10 days. The medium was replaced every
3 days. Flow cytometric test of isolated hEnSCs is per-
formed for hEnSCs markers.
3. Preparation of BG extract. 1 g BG powder was incubated in
5 ml DMEM media for 7 days at 37 C. After that, super-
natant was collected and sterilized with 70 lm filter.
4. Assessment of vasculogenic and angiogenic potentia of BG
powder extract on hEnSCs.
The vasculogenesis potentials of BG on hEnSCs were eval-
uated by using an In Vitro Angiogenesis Assay Kit (Millipore,
Cat. No. ECM625). This kit is useful for testing the effects of
stimulatory or inhibitory exogenous signals such as growth
factors, drugs and toxic agents. The kit includes a solid gel
of basement proteins prepared from laminin, collagen type
IV, heparan sulfate proteoglycans, entactin, and nidogen with-
out any differential factors such as VEGF. We examined the
vasculogenesis, angiogenesis by hEnSCs and HUVEC (as a
control) in a 96-well tissue culture plate. 5  104 hEnSCs/scaf-
fold of the 2nd passage were transferred to each well of kit and
incubated for 12 h at 37 C. Different concentrations of BG
extracts were added to each well, incubated for 6 h at 37 C.
Tube formation is inspected under an inverted light
microscope at 20 magnification. After that, Real-time PCR
analysis is performed to evaluate the expression of a set of
EPCs and endothelial cells gens such as FLT1, PECAM,
ECAD and vWF markers, and immunocytochemistry proce-
dures are performed for studying expression of CD34 and
CD31.
Discussion
Recently, there has been an increasing attentiveness in the
potential of utilizing a cell-based therapy with exogenous
angiogenic agents such as VEGF and FGF-2 proteins to attain
regenerative angiogenesis, vasculogenesis and treatment of
endothelial vascular disorders [33,34]. Previous studies showed
that BG (Fig. 1) possess angiogenic potential over a small
range of concentrations, promote the release of VEGF and
bFGF angiogenic proteins [35]. Endothelial dysfunction in
myocardial infarction [36], brain stroke [37], chronic renal fail-
ure [5], diabetes [38] and hypertension diseases [39,40] are
attributing to decrease number of EPCs and impair activity
of the these cells. An in vivo animal model with acute myocar-
dial or ischemic disorders can be useful to investigate the vas-
culogenic, angiogenic capacity of hEnSCs via the usage of BG
in control or recovery model of disease by ameliorating clinical
symptoms, evaluating cell markers expression in hEnSCs-
derived EPCs and angiogenesis in histological sections (stain-
ing for endothelial cell markers such as vWF or other markers)
of the defect site of rat heart.
Conclusion
The current study reveals that hEnSCs culture with BG extract
can induce spontaneous vasculogenesis and angiogenesis by
enhancing the number of EPCs and endothelial tube forma-
tion, so a possible new application of angiogenic agent (BG)with immuno-privileged, readily available sources of adult
stem cells like human endometrial stem cells will promote a
good choice for endothelial repair and vascular tissue
engineering.Overview box:
First question: What do we already know about the
subject?
Endothelial dysfunction has been betokened as a key
phenomenon in the pathogenesis of ischemic diseases
and coronary vasoconstriction. The application of
hEnSCs with scaffolds and growth factors can be exten-
sively advantageous based on rising proof in the literature
about the multiple differentiation potency of this stem
cell. Also, it has been shown in animal models that bio-
glass delivery to ischemic tissues greatly promote compen-
sative angiogenesis.
Second question: What does your proposed theory add to
current knowledge available and what benefits does it have?
Our hypothesis suggests that using human endometrial
stem cells (as the new source for increasing the number of
endothelial progenitor cells in endothelial dysfunction dis-
eases) with bioglass (angiogenic agent), and also assessing
its relating cellular and molecular processes could be a
promising strategy for treatment of ischemic and endothe-
lial disorders.
Third question: Among numerous available studies, what
special further study is proposed for testing the idea?
We suggest that human endometrial stem cells with
bioglass could propose a suitable new insight for increas-
ing hEnSCs-derived EPCs in vascular tissue engineering.
We induce myocardial infarction in vivo model with coro-
nary ligation in C57BL/6 mice and insertion bioglass-
based scaffold (for controlled release of bioglass ions)
seeded with human endometrial stem cells in mouse
model, to examine the effects of BG material with human
endometrial stem cells in clinical symptom improvement
and assessment of circulating endothelial progenitor cells
number compared to control models without human
endometrial stem cells.Conflict of interest
The authors declare that they do not have any conflict of
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